As of 2026-03-21, the Relative Valuation of Relmada Therapeutics Inc (RLMD) is (15.83) USD. This relative valuation is based on P/E multiples. With the latest stock price at 6.07 USD, the upside of Relmada Therapeutics Inc based on Relative Valuation is -360.8%.
The range of the Relative Valuation is (11.05) - (16.36) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 17.3x | 16.0x |
| Forward P/E multiples | 9.6x - 15.7x | 14.2x |
| Fair Price | (11.05) - (16.36) | (15.83) |
| Upside | -282.1% - -369.6% | -360.8% |
| Date | P/E |
| 2026-03-12 | -5.89 |
| 2026-03-11 | -6.05 |
| 2026-03-10 | -6.34 |
| 2026-03-09 | -6.86 |
| 2026-03-06 | -4.26 |
| 2026-03-05 | -4.24 |
| 2026-03-04 | -4.57 |
| 2026-03-03 | -4.47 |
| 2026-03-02 | -4.63 |
| 2026-02-27 | -4.36 |
| 2026-02-26 | -4.40 |
| 2026-02-25 | -4.35 |
| 2026-02-24 | -4.08 |
| 2026-02-23 | -3.86 |
| 2026-02-20 | -3.95 |
| 2026-02-19 | -4.17 |
| 2026-02-18 | -3.90 |
| 2026-02-17 | -3.48 |
| 2026-02-13 | -3.56 |
| 2026-02-12 | -3.73 |
| 2026-02-11 | -3.83 |
| 2026-02-10 | -3.85 |
| 2026-02-09 | -4.02 |
| 2026-02-06 | -3.71 |
| 2026-02-05 | -3.45 |
| 2026-02-04 | -3.49 |
| 2026-02-03 | -3.64 |
| 2026-02-02 | -3.67 |
| 2026-01-30 | -3.40 |
| 2026-01-29 | -3.74 |
| 2026-01-28 | -3.78 |
| 2026-01-27 | -3.92 |
| 2026-01-26 | -3.80 |
| 2026-01-23 | -3.73 |
| 2026-01-22 | -3.79 |
| 2026-01-21 | -3.65 |
| 2026-01-20 | -3.77 |
| 2026-01-16 | -3.58 |
| 2026-01-15 | -3.64 |
| 2026-01-14 | -3.68 |
| 2026-01-13 | -3.89 |
| 2026-01-12 | -3.93 |
| 2026-01-09 | -4.12 |
| 2026-01-08 | -4.24 |
| 2026-01-07 | -4.13 |
| 2026-01-06 | -3.90 |
| 2026-01-05 | -4.05 |
| 2026-01-02 | -4.18 |
| 2025-12-31 | -4.62 |
| 2025-12-30 | -4.34 |